No Data
Komei Diagnosis: Komei Diagnostic Technology Co., Ltd. 2024 Annual Performance Report Announcement
Kemei Diagnostics (688468.SH): The net income for the fiscal year 2024 is 0.127 billion yuan, a decrease of 13.83% year-on-year.
On February 27, Glory Financial reported that Kemei Diagnostics (688468.SH) released its performance preliminary report for 2024. During the reporting period, the company achieved revenue of 436.2898 million yuan, a decrease of 2.03% compared to the same period last year; operating profit of 134.7509 million yuan, a decline of 18.96% compared to the same period last year; total profit of 137.8276 million yuan, a decrease of 17.03% compared to the same period last year; net income attributable to the parent company's owners of 126.9928 million yuan, a decrease of 13.83% compared to the same period last year; net income attributable to the parent company's owners after deducting non-recurring gains and losses of 10,0.
Chemclin Diagnostics Co., Ltd. (SHSE:688468) Surges 25% Yet Its Low P/E Is No Reason For Excitement
Chemclin Diagnostics Co., Ltd.'s (SHSE:688468) Market Cap Surged CN¥446m Last Week, Private Companies Who Have a Lot Riding on the Company Were Rewarded
Kemei Diagnostics (688468.SH): Shanghai Peixi and its concerted actors have collectively reduced their shareholding by 3%.
Gelonghui, December 19th丨Kemei Diagnosis (688468.SH) announced that on October 14, 2024, the company disclosed the "Announcement of Shareholding Reduction Plan by Shareholders Holding More Than 5% of Kemei Diagnosis Technology Co., Ltd." Shanghai Peixi and its concerted parties HJCAPITAL plan to reduce their shareholding through centralized bidding and block trading, and the total reduction is expected not to exceed 12,033,240 shares, accounting for no more than 3.00% of the company’s total equity. On December 18, 2024, the company received a notice from the above shareholders regarding the implementation results of the share reduction plan.
Co-Rays Diagnostics (688468.SH): Hengqin Junlian Zhi Kang and its concerted parties have cumulatively reduced their shareholding by 1.99%.
Gelonghui, November 6th - Kemei Diagnostics (688468.SH) announced that on November 5, 2024, the company received a brief equity changes report from the company's shareholder Hengqin Junlian ZhiKang and its concerted action person LOYALCLASS. During the period from August 15, 2024 to November 5, 2024. Hengqin Junlian ZhiKang and its concerted action person LOYALCLASS collectively reduced their shareholding in the company by 7,975,214 shares, accounting for 1.99% of the total share capital of the company. After this equity change, Hengqin Junlian ZhiKang and its
Chemclin Diagnostics Co., Ltd.'s (SHSE:688468) Business And Shares Still Trailing The Market
